Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25207968 | 1.00 | EGFR (0.48) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL29382657 | 0.92 | EGFR (0.43) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL25371653 | 0.91 | EGFR (0.42) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL25214129 | 0.91 | EGFR (0.42) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL25239983 | 0.90 | EGFR (0.49) | EGFRERBB2KDR | |
| SCHEMBL25239984 | 0.90 | EGFR (0.49) | EGFRERBB2KDR | |
| SCHEMBL26055465 | 0.89 | EGFR (0.47) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL29382629 | 0.88 | EGFR (0.46) | EGFRERBB2EPHA2EPHB4 | |
| SCHEMBL25663539 | 0.88 | EGFR (0.46) | EGFRERBB2EPHA2EPHB4 | |
| SCHEMBL25663558 | 0.88 | EGFR (0.46) | EGFRERBB2EPHA2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803325-B | EGFR inhibitor and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-115803325-A | EGFR inhibitor and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | EGFR 1/4885ERBB2 5/4885KDR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.